Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology

Professor Bryan King

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. Neurotrope Bioscience
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. Janssen, Roche, Neuren
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. Travel reimbursement for consultation meeting with Neurotrope
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. Janssen, Roche, Neuren
  21. If there is anything else you feel it necessary to disclose, please provide details below:

Form completed on 17th May 2017